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Summary
Background Chagas disease is currently prevalent in European countries hosting large communities from Latin 
America. Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and 
treated accordingly is unclear. We performed an economic evaluation of systematic Chagas disease screening of the 
Latin American population attending primary care centres in Europe.
Methods We constructed a decision tree model that compared the test option (screening of asymptomatic individuals, 
treatment, and follow-up of positive cases) with the no-test option (screening, treating, and follow-up of symptomatic 
individuals). The decision tree included a Markov model with five states, related to the chronic stage of the disease: 
indeterminate, cardiomyopathy, gastrointestinal, response to treatment, and death. The model started with a target 
population of 100 000 individuals, of which 4·2% (95% CI 2·2–6·8) were estimated to be infected by Trypanosoma cruzi. 
The primary outcome was the incremental cost-effectiveness ratio (ICER) between test and no-test options. 
Deterministic and probabilistic analyses (Monte Carlo simulations) were performed.
Findings In the deterministic analysis, total costs referred to 100 000 individuals in the test and no-test option were 
€30 903 406 and €6 597 403 respectively, with a difference of €24 306 003. The respective number of quality-adjusted 
life-years (QALYs) gained in the test and no-test option were 61 820·82 and 57 354·42. The ICER was €5442. In the 
probabilistic analysis, total costs for the test and no-test option were €32 163 649 (95% CI 31 263 705–33 063 593) and 
€6 904 764 (6 703 258–7 106 270), respectively. The respective number of QALYs gained was 64 634·35 (95% CI 
62 809·6–66 459·1) and 59 875·73 (58 191·18–61 560·28). The difference in QALYs gained between the test and no test 
options was 4758·62 (95% CI 4618·42–4898·82). The incremental cost-effectiveness ratio (ICER) was €6840·75 
(95% CI 2545–2759) per QALY gained for a treatment efficacy of 20% and €4243 per QALY gained for treatment 
efficacy of 50%. Even with a reduction in Chagas disease prevalence to 0·05% and with large variations in all the 
parameters, the test option would still be more cost-effective than the no-test option (less than €30000 per QALY).
Interpretation Screening for Chagas disease in asymptomatic Latin American adults living in Europe is a cost-effective 
strategy. Findings of our model provide an important element to support the implementation of T cruzi screening 
programmes at primary health centres in European countries hosting Latin American migrants.
Funding European Commission 7th Framework Program.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Chagas disease is emerging in Europe, where prevalence 
has increased enormously during the past 15 years due to 
migration from Chagas disease endemic countries of 
Latin America.1 The global economic burden of Chagas 
disease has been estimated at about US$7·2 billion a 
year, with around 15% of costs pertaining to non-endemic 
countries, and with the highest cost attributable to 
cardiovascular disease and early mortality.2 30–40% 
of chronically infected individuals develop cardiac 
complications, gastrointestinal complications, or both,3 
but most remain indeterminate (asymptomatic for life 
and with a normal 12-lead electrocardiogram and chest-
radiograph).3 Antiparasitic therapy is effective at curing 
infection in acute, congenital, and early chronic disease.4,5 
The current tendency in both endemic and non-endemic 
countries is to give antiparasitic treatment to chronic 
asymptomatic adults and patients with early 
cardiomyopathy.6 However, this practice is based on 
evidence from only one open-label, non-randomised, 
non-blinded trial and from other longitudinal studies 
that have shown decreased progression of cardiomyopathy 
and mortality.7,8
In Europe, transmission from individuals infected with 
Tripanosoma cruzi (T cruzi), including from those who are 
asymptomatic, occurs either vertically or through 
transfusion of infected blood products or transplantation 
of infected organs.9 Screening programmes are currently 
recommended in blood-banks and transplant settings and 
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have already been implemented in some European 
countries, such as Spain, the UK, and Switzerland.10 
Screening of pregnant women from Latin American 
endemic countries has also been shown to be cost-
effective,11 and has been identified as a priority for Chagas 
disease control in Europe,10 although it has not yet been 
widely implemented.
Among all interventions, the economic value of 
systematically screening—and treating—migrants from 
Chagas disease-endemic countries remains unclear. 
Therefore, we performed an economic evaluation of 
Chagas disease screening of Latin American patients at 
European primary care centres. Previous studies have 
identified primary care centres as key channels through 
which opportunities arise to identify the infection in 
patients from Latin America attending the centre for any 
reason.12,13
Methods
Prevalence of Chagas disease in migrant population
Prevalence was based on country-specific data from a 
recent systematic review and meta-analysis showing 
a random effect pooled Chagas disease prevalence of 
4·2% (95% CI 2·2–6·8) among Latin-American 
migrants.14 The pooled prevalence of Chagas disease by 
country of origin among Latin American migrants in 
European countries is summarised in the appendix (p 1). 
Because the meta-analysis involved studies from France, 
Germany, Italy, Switzerland, and Spain, only costs from 
these five countries were included in this economic 
evaluation. These are also the countries in Europe with 
the highest number of immigrants from Latin America.
Cost-effectiveness model
We developed a decision-tree to compare the 
cost-effectiveness of (1) screening all Latin American 
asymptomatic patients seen at primary health centres, 
treating the positive cases, and following them up with 
periodic visits and interventions (test option) and (2) doing 
nothing actively but screening and treating only 
symptomatic individuals that develop Chagas disease 
complications (no-test option). Within the decision-tree, 
the natural history of the disease was represented through 
a Markov model (figure 1), which is considered the most 
appropriate model for assessing chronic diseases or 
diseases that progress over time, such as Chagas disease.2,15
The Markov model considered each infected person to be 
in one of a finite number of health states related to chronic 
Chagas disease during a 1 year cycle. Every year, each 
patient either remained in the same state or moved to 
another one according to defined transition probabilities 
(figure 1). Costs and utilities in terms of quality-adjusted 
life-years (QALYs) expectancy, a measure of health outcome 
that combines the value of length of life and the quality of 
life into a single indicator,16 were associated with each of the 
five states: indeterminate Chagas disease, cardiac form, 
gastrointestinal form, response to treatment, and death 
(from any cause). As figure 1 shows, in this model, a patient 
could not move from treatment response to the cardiac or 
gastrointestinal forms or from death to any other forms. 
The model terminated when all patients reached the death 
state. The model started with a target population of 
100 000 Latin American individuals from Chagas disease-
endemic countries, and 4·2% (95% CI 2·2–6·8) were 
assumed to be infected with T cruzi.14
The first year-cycle of the model (year 0) starts with 
parameter values taken from the study by Salvador and 
colleagues,17 indicating that 85·8% of individuals infected 
with T cruzi were asymptomatic and that 14·1% of 
asymptomatic patients were in the cardiac form, whereas 
the remainder were in the indeterminate form.17 The 
mean age of the population was set at 35 years.18
In the base case analysis, 80% of the target population 
(patients at risk of Chagas disease) was screened and 
treated. The remaining 20% followed the same disease 
pattern as the individuals in the no-test option, which 
Research in context
Evidence before this study
 We did a systematic search of PubMed using the search terms 
(“Chagas” AND (“cost” OR “economic”) AND “screening”). We 
restricted the search to documents available in English and 
Spanish; the last search was done on Oct 8, 2015. We found 
four articles that evaluated the cost-effectiveness of control 
strategies in LatinAmerica all based in vector control strategies, 
two more articles that evaluated the global cost or the burden 
of Chagas disease, two studies that evaluated the cost-
effectiveness of Chagas disease screening in blood-banks in 
non-endemic areas, and two economic studies of the screening 
of Chagas disease in pregnant women and their infants. 
However, the search did not find any economic studies 
regarding Trypanosoma cruzi screening in asymptomatic chronic 
adults at the primary care level.
Added value of this study
This study is the first to show the cost-effectiveness of a 
strategy of Chagas disease screening at primary care level of 
asymptomatic Latin-American adults living in non-endemic 
areas.
Implications of all the available evidence
Our findings provide an important element to support the 
implementation of a primary care T cruzi screening programme 
in European countries hosting Latin American migrants. 
Other elements should be considered such as the national Latin 
American migrant profiles, national legislations, and health 
system characteristics as well as the acceptability of the 
screening programme.
See Online for appendix
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implies that the probability of developing cardiomyopathy 
was the same in both cases.
Disease states and transition probabilities
In the test option, T cruzi serological screening was 
applied to all Latin American patients; in the event of a 
positive result, a chest radiograph and an annual 
electrocardiogram (ECG) were undertaken. We assumed 
that no false positive or negative tests occurred. According 
to the literature, sensitivity of the most widely used 
serological tests (eg, CLIA recombinant test19) is virtually 
100% and accordingly, some studies recommend that the 
T cruzi screening should be based on a single unique test 
when the test done is an ELISA assay.20 However, it is 
generally held that the infection should be confirmed with 
a second serological test: this was the screening strategy in 
our model. We also considered a 4% presumptive false-
positive cases with the first test, for which a third screening 
was then required to resolve potential discrepancies 
between the first and the second test. Therefore, our 
screening strategy consisted of a unique serological test in 
92%, two tests in 4%, and three tests in 4% of the total 
population screened. Assumption was made that nobody 
would refuse the treatment and all positive cases received 
treatment according to the current clinical practice in non-
endemic areas.17,18 This entails treatment with the 
antiparasitic drug benznidazole for 60 days, as per WHO 
recommendations,21 with complete blood count and basic 
biochemistry monitoring at follow-up visits every 
15 days.17,18 In the no-test option, only symptomatic patients 
transitioning to the cardiac or gastrointestinal forms were 
diagnosed with Chagas disease and treated accordingly.
Based on the literature, the probability of moving from 
the indeterminate form to the cardiac form was set at 2% 
a year for the no-test option (progression to 
cardiomyopathy in untreated patients22) and at 0·5% for 
the test option.7 The probability of moving to the 
gastrointestinal form was conservatively considered at 
0·3% a year for both options based on little evidence that 
antitrypanosomal therapy mitigates the risk of 
progression to intestinal disease.22 The probability of 
death attributable to Chagas disease was 3·9% in patients 
with cardiomyopathy and was set at zero in both 
indeterminate and gastrointestinal forms23 (appendix 
p 2). Possibility of reinfection was not considered.
Age-specific probability of death due to any cause was 
calculated using data from the Spanish Instituto Nacional 
de Estadística.24 These values are similar across European 
countries included in our study.25 Response to treatment 
was defined as conversion to negative of previously 
positive serology as described elsewhere.8,26 Two scenarios 
were considered: a base-case 20% response to treatment, 
5 years after receiving benznidazole, as reported by Viotti 
and colleagues;8 and an assumption of a more optimistic 
50% response to treatment, 5 years after receiving 
benznidazole. Spontaneous positive to negative 
conversion was not considered.
We based values of the probabilities of undertaking 
tests and interventions in the cardiomyopathy and 
gastrointestinal states on the consensus of data from 
two different clinical groups. One group is the 
NHEPACHA network (Nuevas Herramientas para el 
Diagnóstico y la Evaluación del Paciente con Enfermedad 
de Chagas) formed by health professionals who are 
highly experienced in Chagas disease from both 
endemic (Bolivia) and non-endemic areas (Europe); the 
second group was composed of a subgroup of 
researchers from the COHEMI project (Coordinating 
resources to assess and improve HEalth status of 
MIgrants from Latin America). Members of the 
NHEPACHA network provided a value for each 
parameter, which was then discussed, edited where 
needed, and validated by the members of COHEMI. 
The level of uncertainty was increased for these 
parameters because of the absence of evidence-based 
data. The probabilities were as follows: echocardiogram 
100%, Holter ECG monitor study 30%, stress test 8%, 
pacemaker 2%, implantable cardioverter-defibrillator 
3%, electrophysiology study 3%, and transplantation 
1%27 (appendix p 2). Based on the literature, it was 
established that 4·2% of individuals in this state would 
develop congestive heart failure28 and therefore require 
an annual echocardiogram and examination by a 
cardiologist as well as specific medication (beta-
blockers, antihypertensives, and diuretics).
Response to
treatment
Indeterminate
form
Indeterminate
form
Gastrointestinal
form
Gastrointestinal
form
No Chagas
disease
No Chagas
disease
Death
Death
Chagas disease
test
Chagas disease
no test Cardiac form
Cardiac form
Screening 
programme
Non-screening 
programme
Figure 1: Decision-tree for Trypanosoma cruzi screening
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Assumption was made that individuals in the 
gastrointestinal state would need to undergo small bowel 
radiographs (100%), barium enema (100%), oesophageal 
manometry (5%), and surgery (1%; appendix p 2).
Costs
We took the health-care provider perspective to estimate 
costs. The costs of all visits, tests, drugs, and interventions 
were taken from the pricelist of Hospital Clínic-Barcelona 
(Barcelona, Spain), a leading Spanish hospital. The costs 
of adverse event management were also included 
(appendix p 7).
To estimate real costs, all values from the pricelist were 
reduced of an overhead component and, where 
applicable, of a mark-up of 20%. Costs were extrapolated 
to France, Germany, Italy, and Switzerland using the 
WHO Choice cost per bed-day ratios between each 
country and Spain.29 The ratio for Italy and Spain, for 
instance, was 1·10 based on a respective per bed-day cost 
of €476·21 and €433·56. Thus, assuming that a coronary 
artery bypass costs €5484·68 in Spain, this would cost 
€6033·15 (= 5484·68 × 1·10) in Italy (appendix p 7).
Costs of programme uptake (appendix p 8) were 
estimated based on data published by Imaz-Iglesia and 
colleagues30 for Spain. These costs included, among others, 
programme coordination, equipment, travel, and meetings 
for a period of 5 years. Because human resources 
represented the major cost associated with programme 
uptake, estimates from Spain were extrapolated to the 
other countries by applying the purchasing power parity 
(PPP) conversion factor.31 Finally, the cross country average 
and the relative variability were used in the model. No 
additional programme recurrent costs were computed 
beyond the first 5 years of uptake. Costs were discounted 
by 3%.19 Because there was no information in the hospital 
pricelist about traded and non-traded components of costs, 
in a further scenario, all costs, not only those associated 
with programme uptake, were PPP adjusted with the 
exclusion of drug costs, which can be considered traded 
goods (appendix p 2).
QALYs
In the model, length of life resulted from the combination 
of a series of parameters, in particular the probability of 
dying (all causes) and of dying due to Chagas disease. 
The quality weights (utilities) applied were 0·9625 for 
the indeterminate form and 0·7171 (average between 
0·769 for mild cardiomyopathy and 0·6651 for severe 
cardiomyopathy) for the cardiomyopathy and 
gastrointestinal forms.32 QALYs, like costs, were 
discounted by 3%.32
Data analysis
The model was estimated by applying deterministic and 
probabilistic analyses in Microsoft Excel. Deterministic 
analysis was done with mean values for each parameter 
(appendix p 2). Univariate sensitivity analysis was done 
by varying the mean value of each parameter to both 
+100% and –99% or to the minimum or maximum 
feasible value (eg, 0 and 1 if parameters were probabilities). 
Results of the univariate sensitivity analysis were shown 
in a tornado diagram. Three scenarios alternative to the 
base case were depicted: one with a response to treatment 
of 50% (base case 20%); a second one with a prevalence of 
Chagas disease of 20%, corresponding, roughly, to the 
one estimated among Bolivian immigrants (base case 
4·2%); and a third one with PPP adjustments for all costs 
excluding drug costs. A threshold analysis allowed the 
estimation of the cutoff points of Chagas disease 
prevalence and of probability of screen and treat at which 
the choice between the test and no-test options would 
switch. A strategy was considered to be cost-effective if 
the cost per QALY gained was less than the currently 
accepted threshold in Europe of €30 000.33,34
For the probabilistic analysis, parameters were included 
as probability distributions. Probabilistic distributions 
were assigned to parameters based on good research 
practice.35 Because individual data were not available in 
most cases, the standard deviation (SD) of each parameter 
was assumed to be 20% of the mean values (appendix 
p 2), which is an accepted variance to construct parameter 
ranges for probabilistic sensitivity analysis when variance 
is unknown.36 For QALYs, an SD of 10% was considered 
for the indeterminate form’s quality weights because this 
phase is perceived to be quite homogeneous across 
people infected with T cruzi: in the indeterminate phase, 
the infection is asymptomatic and patients are well. In 
the case of clinical service costs, the SD was based on 
estimated costs for each of the five countries.
Probabilistic analysis was performed through Monte 
Carlo simulations. The number of iterations needed to 
produce stable results was based on the graphical 
representation of the cumulative average net 
monetary benefits (threshold level × incremental 
effects – incremental costs). Simulations were graphically 
presented in the cost-effectiveness plane37 and as 
acceptability curves.38 The cost-effectiveness plane plots 
all Monte Carlo simulations produced with respect to 
QALYs gained and incremental costs, allowing 
visualisation of the confidence area delimited by the 95% 
confidence ellipses. Acceptability curves show the 
probability of the test option to be cost-effective according 
to theoretical policy-maker willingness to pay for each 
QALY gained.
The study followed the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) statement 
(appendix p 9).
Role of the funding source
The funder of the study (the European Commission) had 
no role in the study design, data collection, data analysis, 
data interpretation, or writing the report. All authors had 
full access to all study data and had final responsibility 
for the decision to submit for publication.
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Results
For the cost-effectivess model, figure 2 shows the number 
of individuals present at each cycle (year) in each of the 
five health states for the test (figure 2A) and no-test 
(figure 2B) options. At the first cycle of the target population 
of 100 000, 4·2% (n=4200) had Chagas disease, 85·8% of 
them (n=3604) were asymptomatic, and 14·1% (n=505) of 
them had an underlying cardiomyopathy despite being 
asymptomatic. Considering an 80% probability of being 
screened, 3099 individuals were finally screened in the 
base case analysis. The number of individuals in the 
indeterminate form decreased over time (figure 2A; dark 
blue line). In the test option the line is discontinuous 
because 5 years after treatment (year 5), 20% of individuals 
would seroconvert and move to response to treatment 
(figure 2A; orange line). The number of individuals with 
the cardiac form (figure 2B; green line) was higher in the 
no-test option at all timepoints. The number of deaths in 
the no-test option increased faster over time (figure 2C).
Results of the deterministic and probabilistic cost-
effectiveness analyses are reported in the table. For the 
deterministic analysis, the total cost in the test option was 
€30 903 406, whereas this was €6 597 403 in the no-test 
option, with a difference of €24 306 003. However, the 
respective number of QALYs gained in the test option was 
61 820·82 and in the no-test option was 57 354·42. The 
incremental cost-effectiveness ratio (ICER) was €5442.
In the univariate sensitivity analysis, the structural 
parameters of the model, such as the probabilities of 
screening and treatment, Chagas disease prevalence, and 
proportion of asymptomatic individuals, had the strongest 
influence on the ICER (appendix p 11). In particular, a 
drop in the probability of screening and treatment (from 
80% to 10%) would determine the intervention to be 
largely not cost-effective (ICER €57 000 per QALY gained). 
With a 99% drop in Chagas disease prevalence and in the 
probability to be asymptomatic down to 0·042% and 
0·858%, respectively, the intervention would no longer be 
cost-effective. Neither an increase nor a decrease in any 
other parameter would change the choice from test to no-
test option. However, the ICER was sensitive to utilities 
used for QALYs estimates and to the probability of 
transplant and of response to treatment (appendix p 11) as 
well as to costs of pacemaker, automated defibrillator, and 
transplant. Costs associated with medical visit, 
echocardiogram, and benznidazole affected the ICER to a 
lesser extent (appendix p 11). The results were also 
affected by the discount rate used (appendix p 11). Most 
probabilities and costs (appendix p 11) had a negligible 
effect on the ICER.
In the threshold analysis, figure 3A shows that even 
with a drop in Chagas disease prevalence to 0·05%, the 
test option would still remain more cost-effective than 
the no-test option (less than €30 000 per QALY gained). 
Below this critical value the ICER would rapidly increase 
to infinity. The cost-effectiveness ratio increased with 
decreased probability of screening and treatment 
(figure 3B) up to a critical value of about 20%—for lower 
values the ICER increased exponentially.
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Figure 2: Markov model—number of individuals in each state at each cycle
Test option (A), no-test option (B), and detail of number of deaths in the test and no-test option (C). In (C) cycles 
start at 1 because there are no deaths at cycle 0.
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The ICER decreased to €5235 per QALY gained for a 
calculated Chagas disease prevalence of 20%. With a 
higher response to treatment of 50%, the ICER decreased 
to €4243 per QALY gained. With all costs, excluding drug 
costs, being PPP adjusted, the ICER decreased to 
€3704 per QALY gained (appendix p 1).
In the probabilistic analysis, about 1500 random 
iterations of the cost-effectiveness model were required to 
achieve stable results. Thus, with 2000 iterations the 
results of the model can be considered stable (appendix 
p 13). Separate simulations were undertaken for costs, for 
QALYs, for their respective differences, and for the ICER.
For a target of 100 000 individuals, the total cost of 
screening, benznidazole treatment, follow-up of positive 
patients plus the costs corresponding to patients who 
developed cardiac and gastrointestinal involvement and 
the cost of the scaling-up of the screening programme 
was €32 163 649 (95% CI 31 263 705–33 063 593) in the test 
option and €6 904 764 (6703 258–7106 270) in the no test 
option. The respective number of QALYs gained were 
64 634·35 (95% CI 62 809·6–66 459·1) in the test option 
and 59 875·73 (58 191·18–61 560·28) in the no-test option 
(table). The ICER was €6840·75 (95% CI 6255·75–7425·75) 
per QALY gained. With PPP adjustment of all costs, the 
ICER was €4666·93 (95% CI 4490·93–4842·93).
The cost-effectiveness plane (appendix p 14) shows the 
differences in costs and effects between the test and no-
test options. The x axis represents the QALYs gained by 
the option test in comparison with the no-test option, 
whereas the y axis represents the incremental costs. All 
the simulation dots are situated below and to the right of 
the threshold limit (yellow line on appendix p 14) 
indicating that the test option, in comparison with the 
no-test option, is cost-effective.
The acceptability curve (appendix p 15) shows that, 
below a theoretical willingness to pay of about €5000 per 
QALY gained, the probability that the test option was 
more cost-effective than the no-test option was zero. This 
probability rapidly increased from zero to 1 when 
augmenting the willingness to pay from €5000 to €7000 
per QALY gained. The probability remained equal to 1 at 
any higher willingness to pay level.
Discussion
Our model found that screening for T cruzi in 
asymptomatic adults at risk of being infected, treating 
and following up those testing positive, is a cost-effective 
strategy in European countries with the highest number 
of immigrants from Latin America. The cost per QALY 
gained is much lower than the currently accepted 
threshold of €30 000 per QALY in Spain33 and other 
European countries;34 furthermore, it is no higher than 
that reported for other common infectious diseases in 
migrants in Europe such as hepatitis B or C.39
Our findings were robust to wide ranges of parameter 
alterations both deterministically and probabilistically. The 
cost-effectiveness reported in this study is based on the 
pooled Chagas disease prevalence of 4·2% estimated for 
Latin American migrants in Europe in a recent meta-
analysis.14 The high heterogeneity of prevalence in Latin 
American migrants from different countries, and even 
different regions within each country, complicates the 
interpretation of our results. For example, Chagas disease 
is more prevalent in migrants from Bolivia and Paraguay 
than from Brazil and Peru, and prevalence rates also vary 
by host country depending on the origin of migrants.14 Italy, 
for instance, has a high proportion of people from Andean 
countries, whereas Spain has received immigrants from 
both Andean and non-Andean countries.40 Other 
sociodemographic characteristics, such as level of education 
and socioeconomic status, also vary. Finally, changes in 
migratory flows also need to be considered because they 
Deterministic analysis Probabilistic analysis
Costs € QALYs Δ Costs € Δ QALYs ICER Costs € 
(95% CI)
QALYs 
(95% CI)
Δ Costs € 
(95% CI)
Δ QALYs 
(95% CI)
ICER (95% CI)
Base case estimate
Test 30 903 406 61 820·82 24 306 003 4466·39 5442 32 163 649 
(31 263 705–
33 063 593)
4758·62 
(4581·31–
4935·93)
25 258 884 
(24 551 659–
25 966 109)
6405·38 
(6159·9–
6650·86)
6840·75 
(6255·75–
7425·75)
No test 6 597 403 57 354·42 ·· ·· ·· 6 904 764 
(6 703 258–
7 106 270)
59 875·73 
(58 191·18 
–61 560·28)
·· ·· ··
All potentially non-traded cost PPP adjusted
Test 20 695 827 61 820·82 16 342 853 4466·39 3659·07 21 127 781 
(20 539 624–
21 715 938)
63 238.46 
(61 423·77–
65 053·15)
16 678 850 
(162 17 740–17 
139 960)
4680·95 
(4502·78–
4859·11)
4666·93 
(4490·93–
4842·93)
No test 43 52 974 57 354·42 .. ·· ·· 4 448 931 
(4 317 232–
4 5 80 631)
58 557·52 
(56 885·95-
60 229·08)
.. ·· ··
QALYs and ICER have been estimated under the base case scenario of 20% response to treatment. QALYs=quality-adjusted life-years. ICER=incremental cost-effectiveness 
ratio. Δ=incremental. PPP=purchasing power parity.
Table: Deterministic and probabilistic results of the cost-effectiveness analysis for Trypanosoma cruzi screening at primary health-care level
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could change the scenarios contemplated in the near 
future. Dynamic models that consider demographic and 
migration flows could therefore be a reasonable strategy to 
adapt the results of this study to different contexts.
A major question regarding the implementation of a 
T cruzi screening programme is whether the intervention 
should target all Latin American migrants or just specific 
high-risk groups. If pooled prevalence rates such as that 
used in our study are considered, the decision is easier 
because cross-country differences do not have to be 
contemplated. Our results show that systematic 
screening is a cost-effective strategy in countries where 
the prevalence of infection in the population being 
screened is above 0·05%. Another strategy might be to 
implement screening by country of origin according to a 
threshold above which this practice is recommended. 
The ICER of €6280 per QALY obtained for a threshold 
prevalence of 1% is acceptable, but it would only be 
applicable to migrants from Argentina, Bolivia, 
El Salvador, Honduras, Mexico, Nicaragua, and Paraguay. 
Furthermore, such a system might be complicated to 
implement in clinical practice, because it would require 
health professionals to be familiar with Chagas disease 
prevalence rates according to country of provenance. 
This system also still fails to take account of important 
within-country heterogeneity.
Interestingly, the acceptability curve shows that policy-
makers should be willing to pay at least about €5000 per 
QALY gained. Any investment lower than this minimum 
value would not lead to a cost-effective result. Legislative 
differences across Europe represent another challenge in 
the implementation of Chagas disease screening 
programmes, because not all undocumented migrants 
have free or full access to health care, and therefore huge 
proportions of the at-risk population could be excluded.
Our study considered the costs of intervention uptake 
to the national level, including human resources to 
coordinate the programme as well as equipment. The 
inclusion of such costs was conservative because the 
diagnostic tests needed to detect Chagas disease might 
not require additional structural costs to national health 
systems, and furthermore, laboratories would not need 
additional equipment to test for Chagas disease in most 
European countries.
The results of our cost-effectiveness study were based 
on a treatment efficacy of 20%.8 However, we also 
contemplated a more optimistic rate of 50%, which 
substantially improved the ICER, based on new data for 
PCR follow-up testing suggesting that the efficacy of 
benznidazole (or at least the antiparasitic efficacy) in 
chronic Chagas disease could be higher than previously 
believed.41
In the base case analysis, the model considered that 
80% of the target population would be finally screened 
and treated. This high coverage level is optimistic 
because it is unlikely that the 80% of target population 
can be reached at primary health centres without 
additional effort and additionally optimistic that this 80% 
would accept the screening and remain adherent to 
treatment. Not surprisingly, in the univariate sensitivity 
analysis, a decrease in this parameter had the largest 
effect on ICER increase. However, even with 20% 
coverage the ICER remained below €30 000 per QALY 
gained. Slightly below 20% coverage the ICER increased 
exponentially, implying that 20% represents a lower 
boundary below which the intervention does not add any 
benefit to the current strategy of screening and treating 
only symptomatic cases.
The model incorporates several simplifications. We 
assumed that all individuals who accepted the screening 
would receive and adhere to antiparasitic treatment. No 
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Figure 3: Threshold sensitivity analysis of the incremental cost-effectiveness ratio (ICER)
Relationship between ICER and Chagas disease prevalence (A); detail of the relationship between ICER and Chagas 
disease prevalence when disease prevalence is between 0 and 0·5% (B); and relationship between ICER and 
probability of screen and treat (C). QALY=quality-adjusted life-years.
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evidence has been published on the acceptance and 
adherence to Chagas disease treatment. However, in our 
clinical experience, almost nobody has ever refused the 
treatment. Some patients might experience difficulties in 
adhering completely to the antiparasitic treatment for 
several reasons, including side-effects. However, even 
with a relevant reduction of efficacy of the treatment, the 
strategy to test remained cost-effective in our model.
The model did not include a state for individuals 
negative for Chagas disease; equally, it did not include 
individuals initially symptomatic. Indeed, the model was 
specifically constructed to decide whether asymptomatic 
individuals likely to have been exposed to the infection in 
the past should be tested, treated, and followed up.
No evidence is available on the probabilities of doing 
tests and interventions in the cardiac and gastrointestinal 
forms. This absence is because Chagas disease is still an 
emerging health problem in non-endemic countries. In 
endemic areas, tests and treatments currently used in 
non-endemic countries might not be available because of 
insufficient resources. To overcome this knowledge gap, 
we estimated key clinical parameters by experts’ opinion, 
leaving a large uncertainty around their true values. 
However, these parameters did not have a large effect on 
our model and should not have led to inaccurate results.
Response to treatment was only considered in 
individuals with the indeterminate form of the disease, 
whereas patients with Chagas disease and cardiac or 
gastrointestinal involvement were not allowed to convert 
to a seronegative condition after treatment. Recent 
results of the BENEFIT trial support this premise 
showing that benznidazole treatment for chronic Chagas 
cardiomyopathy did not reduce cardiac clinical 
deterioration through 5 years of follow-up.42
Transition from the gastrointestinal to the cardiac form 
was also not allowed, and it was therefore assumed that no 
patients simultaneously developed cardiac and digestive 
complications. Additionally, we contemplated the same 
treatment for severe cardiomyopathy for all patients. 
Standard deviation for parameters was set at 20% for all 
parameters except QALYs in the indeterminate form (10%). 
This was done under the assumption that the indeterminate 
phase is quite homogeneous across people infected with 
T cruzi. This is different from the quality of life of patients 
in the cardiac and gastrointestinal forms. Cardiac and 
gastrointestinal problems are associated with a wide 
spectrum of manifestations, from less severe to very severe 
signs and symptoms. As a consequence; the associated 
quality of life has a wider range of uncertainty.
As mentioned earlier, the variability of the nationalities 
of migrants coming from endemic areas living in each 
European country might also be a limitation when 
interpreting the results and providing recommendations 
in each country.
Quality weights used were not elicited from individuals 
affected by Chagas disease across Europe but derived 
from a previous study in which utilities were equally not 
directly measured.32 Little knowledge is available about 
the quality of life of patients with Chagas disease from 
endemic areas43 and no knowledge from non-endemic 
areas. The measurement of quality of life of patients with 
Chagas disease in non-endemic areas should be set as a 
priority in the research agenda.
Finally, we did not consider the potential negative effect 
of a positive T cruzi test on an individual’s quality of life. 
Knowledge that the individual has the disease could 
negatively affect quality of life, at least in the short term. 
However, this is difficult to measure in practice.44
Our study did not assess the effect of screening and 
treatment on the reduction of the vertical transmission of 
T  cruzi infection;45 this could be another important 
benefit of screening at-risk women of childbearing age.
Screening asymptomatic adult Latin American migrants 
for Chagas disease in western Europe and treating T cruzi-
seropositive individuals with antiparasitic therapy and 
following them up in the long term is a cost-effective 
strategy. Our findings provide an important element to 
support the implementation of a primary care T cruzi 
screening programme. However, other factors should be 
considered such as the heterogeneity of national legislations 
and of health system characteristics as well as users’ 
acceptability of the screening programme.
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